[go: up one dir, main page]

EP0759979A4 - Antisense inhibition of hepatitis c virus - Google Patents

Antisense inhibition of hepatitis c virus

Info

Publication number
EP0759979A4
EP0759979A4 EP95919104A EP95919104A EP0759979A4 EP 0759979 A4 EP0759979 A4 EP 0759979A4 EP 95919104 A EP95919104 A EP 95919104A EP 95919104 A EP95919104 A EP 95919104A EP 0759979 A4 EP0759979 A4 EP 0759979A4
Authority
EP
European Patent Office
Prior art keywords
hepatitis
virus
antisense inhibition
antisense
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95919104A
Other languages
German (de)
French (fr)
Other versions
EP0759979A1 (en
Inventor
Takaji Wakita
Jack R Wands
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP0759979A1 publication Critical patent/EP0759979A1/en
Publication of EP0759979A4 publication Critical patent/EP0759979A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP95919104A 1994-05-10 1995-05-08 Antisense inhibition of hepatitis c virus Withdrawn EP0759979A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24038294A 1994-05-10 1994-05-10
US240382 1994-05-10
PCT/US1995/005812 WO1995030746A1 (en) 1994-05-10 1995-05-08 Antisense inhibition of hepatitis c virus

Publications (2)

Publication Number Publication Date
EP0759979A1 EP0759979A1 (en) 1997-03-05
EP0759979A4 true EP0759979A4 (en) 1999-10-20

Family

ID=22906305

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95919104A Withdrawn EP0759979A4 (en) 1994-05-10 1995-05-08 Antisense inhibition of hepatitis c virus

Country Status (4)

Country Link
US (1) US6001990A (en)
EP (1) EP0759979A4 (en)
JP (1) JPH10503364A (en)
WO (1) WO1995030746A1 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA964446B (en) * 1995-06-06 1996-12-06 Hoffmann La Roche Oligonucleotides specific for hepatitis c virus
IT1297096B1 (en) * 1997-12-03 1999-08-03 Sorin Diagnostics S R L METHOD FOR THE DETECTION OF SINGLE HELIX DNA ANALYTES
EP1002878A3 (en) * 1998-11-19 2003-11-12 Tosoh Corporation Hepatitis C Virus RNA-binding oligo DNA and method preparing it
DK1309726T4 (en) * 2000-03-30 2019-01-28 Whitehead Inst Biomedical Res RNA Sequence-Specific Mediators of RNA Interference
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP2002125688A (en) * 2000-10-30 2002-05-08 Tosoh Corp Oligonucleotides and detection method for sensitive detection of hepatitis C virus
WO2002044717A1 (en) * 2000-12-01 2002-06-06 Cornell Research Foundation Animal model for flaviviridae infection
KR100872437B1 (en) 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Small RNA molecules that mediate JR interference
AU2002311897A1 (en) * 2001-05-09 2002-11-18 Third Wave Technologies, Inc. Nucleic acid detection in pooled samples
US10590418B2 (en) * 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
EP1409506B1 (en) 2001-07-23 2012-05-09 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for rnai mediated inhibition of gene expression in mammals
WO2003026589A2 (en) * 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
EP1352960A1 (en) * 2002-04-12 2003-10-15 Viruvation B.V. Antiviral therapy on the basis of RNA interference
CA2489895A1 (en) * 2002-07-26 2004-02-05 Abbott Laboratories Method of detecting and quantifying hepatitis c virus
US20040024193A1 (en) * 2002-07-26 2004-02-05 Williams Gregg T. Method of detecting and quantifying hepatitis C virus
US20050058982A1 (en) 2002-07-26 2005-03-17 Chiron Corporation Modified small interfering RNA molecules and methods of use
US20040241854A1 (en) 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20080176812A1 (en) * 2002-08-05 2008-07-24 Davidson Beverly L Allele-specific silencing of disease genes
US20050106731A1 (en) * 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
US20050255086A1 (en) * 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US20050042646A1 (en) * 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20040023390A1 (en) * 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
FR2848572B1 (en) * 2002-12-12 2005-12-09 Univ Joseph Fourier INHIBITOR MOLECULES OF PROTEIN SYNTHESIS OF HEPATITIS C VIRUS AND METHOD FOR SCREENING THESE INHIBITORY MOLECULES
US20060128617A1 (en) * 2003-01-24 2006-06-15 Tokyo Metropolitan Organization For Medical Research Oligoribonucleotide or peptidic nucleic acid inhibiting function of hepatitis c virus
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
EP2270162B1 (en) * 2003-06-12 2018-10-03 Alnylam Pharmaceuticals Inc. Conserved hbv and hcv sequences useful for gene silencing
ATE494373T2 (en) 2004-05-04 2011-01-15 Univ Leland Stanford Junior METHODS AND COMPOSITIONS FOR REDUCING AMOUNTS OF HCV VIRUS IN A TARGET CELL
AU2011250867A1 (en) * 2004-05-04 2011-12-08 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for reducing viral genome amounts in a target cell
US20090170794A1 (en) * 2004-09-10 2009-07-02 Somagenics Inc. Small interfering rnas that efficiently inhibit viral expression and methods of use thereof
EP2325314B1 (en) 2004-09-24 2014-08-20 Alnylam Pharmaceuticals, Inc. Targeting opposite strand replication intermediates of single-stranded viruses by RNAI
WO2007052629A1 (en) * 2005-11-01 2007-05-10 Nippon Shinyaku Co., Ltd. Oligo double-stranded rna and pharmaceutical composition
WO2007084567A2 (en) * 2006-01-17 2007-07-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Detection and discrimination of hepatitis c virus, human immunodeficiency virus type-1 and hepatitis b virus
JP5198430B2 (en) 2006-04-03 2013-05-15 サンタリス ファーマ アー／エス Pharmaceutical composition comprising antimiRNA antisense oligonucleotide
EP3502255A1 (en) 2006-04-03 2019-06-26 Roche Innovation Center Copenhagen A/S Pharmaceutical composition
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
CA2681406A1 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
DK2205737T3 (en) 2007-10-04 2013-05-21 Santaris Pharma As Micromirers
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
EP2315832B1 (en) 2008-08-01 2015-04-08 Roche Innovation Center Copenhagen A/S Micro-rna mediated modulation of colony stimulating factors
EP2352744B1 (en) 2008-10-15 2016-09-21 Somagenics, Inc. Short hairpin rnas for inhibition of gene expression
WO2010122538A1 (en) 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
EP2454371B1 (en) 2009-07-13 2021-01-20 Somagenics, Inc. Chemical modification of small hairpin rnas for inhibition of gene expression
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
US9506030B2 (en) 2013-05-01 2016-11-29 Regulus Therapeutics Inc. Compounds and methods for enhanced cellular uptake
SG11201508925WA (en) 2013-05-01 2015-11-27 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
DK3013959T3 (en) 2013-06-27 2020-02-17 Roche Innovation Ct Copenhagen As ANTISENSE OLIGOMERS AND CONJUGATES TARGETED PCSK9
JOP20200092A1 (en) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
CN112400020B (en) 2018-05-08 2024-11-19 莱古路斯治疗法股份有限公司 GALNAC-conjugated modified oligonucleotides as MIR-122 inhibitors with HCV antiviral activity and reduced hyperbilirubinemia side effects
UA127745C2 (en) 2018-08-13 2023-12-20 Альнілам Фармасьютікалз, Інк. COMPOSITIONS CONTAINING AN AGENT BASED ON HEPATITIS B VIRUS (HBV) dsRNA AND METHODS OF USING THEM

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012992A2 (en) * 1991-01-14 1992-08-06 James N. Gamble Institute Of Medical Research Basic structural immunogenic polypeptides having epitopes for hcv, antibodies, polynucleotide sequences, vaccines and methods
CA2104649A1 (en) * 1992-08-25 1994-02-26 Makoto Seki Antisense compounds complementary to hcv genome
WO1994005813A1 (en) * 1992-09-10 1994-03-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Compositions and methods for treatment of hepatitis c virus-associated diseases
WO1994008002A2 (en) * 1992-09-28 1994-04-14 Chiron Corporation Methods and compositions for controlling translation of hcv proteins

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) * 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US4789734A (en) * 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
US4925673A (en) * 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
EP0384566A3 (en) * 1989-01-27 1991-11-13 The Wistar Institute Amplification of htlv-1 sequences from multiple sclerosis patients
UA50829C2 (en) * 1989-03-17 2002-11-15 Чірон Корпорейшн Polynucleotide, vector, cells, expressing system, polypeptides, monoclonal antibodies, preparation of polyclonal antibodies, nucleotide probe, analytic kits, method for detecting nucleic acids, methods for immunoassay, vaccine, method for production of antibodies
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
US5399345A (en) * 1990-05-08 1995-03-21 Boehringer Mannheim, Gmbh Muteins of the granulocyte colony stimulating factor
JPH06500928A (en) * 1990-08-29 1994-01-27 ザ・ウイスター・インスティテュート・オブ・アナトミー・アンド・バイオロジー Methods for diagnosing and treating chronic fatigue immunodeficiency syndrome and compositions therefor
WO1992009634A1 (en) * 1990-11-29 1992-06-11 Toray Industries, Incorporated Non-a non-b hepatitis virus antigen protein
CA2108466C (en) * 1991-05-08 2007-07-10 Tai-An Cha Hcv genomic sequences for diagnostics and therapeutics
UA43310C2 (en) * 1991-06-10 2001-12-17 Лакі Лімітед POLYPEPTIDE OF KOREAN TYPE VIRUS HEPATITIS C (KHCV), cDNA (KHCV), POLYNUCLEOTIDE ENCODING POLYPEPTIDE (KHCV), RECOMBINANT EXPRESSING VECTOR, CELL, TRANSFORMED BY VECTOR, POLYPEPTIDE COMPRISING EPITOPE, PROCESS FOR OBTAINING POLYPEPTIDE, DIAGNOSTIC AGENT FOR DETECTING ANTIBODY, DIRECTED AGAINST (KHCV) ANTIGENE, DIAGNOSTIC KIT, DIAGNOSTIC METHOD FOR DETECTING OF ANTIBODY, DIRECTED AGAINST (KHCV) ANTIGENE, MONOCLONAL ANTIBODY, CELL LINE, DIAGNOSTIC AGENT FOR DETECTING OF EPITOPE (KHCV) IN THE SAMPLE, WHICH IS TESTED, METHOD FOR DETECTING OF EPITOPE (KHCV), VACCINE FOR TREATING AND PREVENTION (KHCV) INFECTION (VARIANTS), KIT FOR DETECTING POLYNUCLEOTIDE (KHCV), METHOD FOR DETECTING POLYNUCLEOTIDE FROM KHCV
KR950014915B1 (en) * 1991-06-19 1995-12-18 주식회사녹십자 Asialoglycoprotein-conjugated compounds
AU671967B2 (en) * 1991-11-21 1996-09-19 Common Services Agency Hepatitis-C virus testing
AU4387193A (en) * 1992-05-29 1993-12-30 Abbott Laboratories Ligase chain reaction starting with rna sequences
JP2778886B2 (en) * 1992-10-16 1998-07-23 エバーニュー バイオテック インコーポレイティド Hepatitis C virus core antigen protein and diagnostic method and kit using the same
US5559028A (en) * 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012992A2 (en) * 1991-01-14 1992-08-06 James N. Gamble Institute Of Medical Research Basic structural immunogenic polypeptides having epitopes for hcv, antibodies, polynucleotide sequences, vaccines and methods
CA2104649A1 (en) * 1992-08-25 1994-02-26 Makoto Seki Antisense compounds complementary to hcv genome
WO1994005813A1 (en) * 1992-09-10 1994-03-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Compositions and methods for treatment of hepatitis c virus-associated diseases
WO1994008002A2 (en) * 1992-09-28 1994-04-14 Chiron Corporation Methods and compositions for controlling translation of hcv proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
See also references of WO9530746A1 *
WAKITA T ET AL: "INHIBITION OF HEPATITIS C VIRUS ANTIGEN EXPRESSION BY ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST 5' NONCODING REGION RIBOSOMAL BINDING SITES", HEPATOLOGY, vol. 18, no. 4, PART 02, 1 October 1993 (1993-10-01), pages 77A, XP000603285, ISSN: 0270-9139 *
WAKITA T ET AL: "SPECIFIC INHIBITION OF HEPATITIS C VIRUS EXPRESSION BY ANTISENSE SPECIFIC OLIGODEOXYNUCLEOTIDES. IN VITRO MODEL FOR SELECTION OF TARGET SEQUENCE.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 19, 13 May 1994 (1994-05-13), pages 14205 - 14210 142, XP000604710, ISSN: 0021-9258 *
WU G Y ET AL: "DELIVERY SYSTEMS FOR GENE THERAPY", BIOTHERAPY, vol. 3, 1991, pages 87 - 95, XP000764198, ISSN: 0921-299X *

Also Published As

Publication number Publication date
EP0759979A1 (en) 1997-03-05
WO1995030746A1 (en) 1995-11-16
JPH10503364A (en) 1998-03-31
US6001990A (en) 1999-12-14

Similar Documents

Publication Publication Date Title
EP0759979A4 (en) Antisense inhibition of hepatitis c virus
EP0837951A4 (en) Antisense inhibition of hepatitis b virus replication
PL324906A1 (en) Vaccines against viral hepatitis of c type
PL321966A1 (en) Vaccine against viral hepatitis of b type
HU9402822D0 (en) Antisense oligonucleotide inhibition of papillomavirus
NZ290318A (en) Compositions comprising antisense oligonucleotides for use against hepatitis b viral replication
AP9200412A0 (en) Compounds and methods for inhibition of hiv and related viruses
AU4794593A (en) Antisense viruses and antisense-ribozyme viruses
PL311736A1 (en) Derivatives of 1h-imidazoles
GB9415369D0 (en) Mutant virus
NZ307494A (en) Lymphokine capable of inhibiting immunodeficiency viruses
PL312692A1 (en) New derivatives of dialkoxy-pyridinol-benzimidazole
EP0833668A4 (en) Inhibition of hepatitis b replication
AU2970595A (en) Inhibition of virus by nitric oxide
ZA964446B (en) Oligonucleotides specific for hepatitis c virus
GB9425604D0 (en) Peptides effective for diagnsis of hepatitis C infection
GB9006924D0 (en) Prognosis of hepatitis infection
GB9209669D0 (en) Novel plant virus sequences
EP0879055A4 (en) Inhibition of viral replication
GB8914680D0 (en) Prevention of aid virus
HU0400424D0 (en) Hepatitis virus vaccines
GB9420956D0 (en) Virus
GB9108030D0 (en) An antisense"aids"virus
HU9502420D0 (en) 3-substituted-2-oxindoles as inhibitors of viral replication
GB9213362D0 (en) Hcv-3 virus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19961209

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE ES FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 19990903

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): CH DE ES FR GB IT NL

RBV Designated contracting states (corrected)

Designated state(s): CH DE ES FR GB IT LI NL

17Q First examination report despatched

Effective date: 20010704

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050908